Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/14482
Title: Edelfosine-induced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosis
Author: Selivanov, Vitaly A.
Vizan Arroyo, José Luis
Mollinedo García, Faustino
Fan, Teresa W. M.
Lee, Paul W. N.
Cascante i Serratosa, Marta
Keywords: Càncer
Metabolisme cel·lular
Cancer
Cell metabolism
Issue Date: 6-Oct-2010
Publisher: BioMed Central
Abstract: Background: Metabolic flux profiling based on the analysis of distribution of stable isotope tracer in metabolites is an important method widely used in cancer research to understand the regulation of cell metabolism and elaborate new therapeutic strategies. Recently, we developed software Isodyn, which extends the methodology of kinetic modeling to the analysis of isotopic isomer distribution for the evaluation of cellular metabolic flux profile under relevant conditions. This tool can be applied to reveal the metabolic effect of proapoptotic drug edelfosine in leukemia Jurkat cell line, uncovering the mechanisms of induction of apoptosis in cancer cells. Results: The study of 13C distribution of Jukat cells exposed to low edelfosine concentration, which induces apoptosis in ¿5% of cells, revealed metabolic changes previous to the development of apoptotic program. Specifically, it was found that low dose of edelfosine stimulates the TCA cycle. These metabolic perturbations were coupled with an increase of nucleic acid synthesis de novo, which indicates acceleration of biosynthetic and reparative processes. The further increase of the TCA cycle fluxes, when higher doses of drug applied, eventually enhance reactive oxygen species (ROS) production and trigger apoptotic program. Conclusion: The application of Isodyn to the analysis of mechanism of edelfosine-induced apoptosis revealed primary drug-induced metabolic changes, which are important for the subsequent initiation of apoptotic program. Initiation of such metabolic changes could be exploited in anticancer therapy.
Note: Reproducció del document publicat a http://dx.doi.org/10.1186/1752-0509-4-135
It is part of: BMC Systems Biology, 2010, 4:135
Related resource: http://dx.doi.org/10.1186/1752-0509-4-135
URI: http://hdl.handle.net/2445/14482
ISSN: 1752-0509
Appears in Collections:Articles publicats en revistes (Institut de Biomedicina (IBUB))
Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
Publicacions de projectes de recerca finançats per la UE

Files in This Item:
File Description SizeFormat 
1752-0509-4-135-S1.PDFFigures477.75 kBAdobe PDFView/Open
584363.pdfDocument876.78 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons